Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 8)*
|
Alphatec Holdings, Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
02081G102 (CUSIP Number) |
Jeffrey Wade c/o LS Power Development, LLC, 1700 Broadway 35th Floor New York, NY, 10019 212-547-2914 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
02/04/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 02081G102 |
| 1 |
Name of reporting person
L-5 Healthcare Partners, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,214,698.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
6.45 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Percentage of class in row (13) represented by amount in row (11) is based on a denominator consisting of 141,815,115 shares of Common Stock outstanding as reported in the Issuer's Form S-3ASR filed on November 15, 2024, together with 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer.
SCHEDULE 13D
|
| CUSIP No. | 02081G102 |
| 1 |
Name of reporting person
Paul Segal | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,214,698.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
6.45 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Amounts shown in row 8 and row 10 represent 9,214,698 shares of Common Stock held by L-5 Healthcare Partners, LLC. Percentage of class in row (13) represented by amount in row (11) is based on a denominator consisting of 141,815,115 shares of Common Stock outstanding as reported in the Issuer's Form S-3ASR filed on November 15, 2024, together with 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer.
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.0001 per share |
| (b) | Name of Issuer:
Alphatec Holdings, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
1950 Camino Vida Roble, Carlsbad,
CALIFORNIA
, 92008. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | Item 5 of this Schedule 13D is hereby amended and restated in its entirety as follows: The information contained on the cover pages to this Schedule 13D is incorporated herein by reference. The aggregate percentage of Common Stock reported owned by each person named herein is based upon 141,815,115 shares of Common Stock outstanding as of November 13, 2024, which is the total number of shares of Common Stock outstanding as reported in the Issuer's Form S-3ASR filed with the Securities and Exchange Commission on November 15, 2024, together with 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer. L-5 directly holds 9,214,698 shares of Common Stock (which includes 8,081,538 shares of Common Stock and 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer) reported in this Schedule 13D. As a result of his relationship with L-5, Paul Segal may be deemed the beneficial owner of all such shares of Common Stock. Mr. Segal, however, disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest therein. |
| (b) | The information set forth in Item (5)(a) of this Schedule 13D is incorporated by reference in its entirety into this Item 5(b). |
| (c) | The transactions effected by the Reporting Persons during the past 60 days are set forth on Schedule 1 attached hereto. |
| (d) | Not applicable. |
| (e) | Not Applicable. |
| Item 7. | Material to be Filed as Exhibits. |
Schedule of Transactions for Item 5(c) of Amendment No. 8. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|